Lbp Am Sa Acquires 6,576 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

LBP AM SA grew its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 120.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,025 shares of the biotechnology company's stock after acquiring an additional 6,576 shares during the period. LBP AM SA's holdings in BioMarin Pharmaceutical were worth $850,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of BMRN. Farther Finance Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 95.9% in the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 211 shares in the last quarter. LRI Investments LLC increased its holdings in BioMarin Pharmaceutical by 856.9% in the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock valued at $32,000 after buying an additional 437 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of BioMarin Pharmaceutical by 71.2% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company's stock valued at $37,000 after buying an additional 218 shares in the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of BioMarin Pharmaceutical by 64.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 233 shares during the period. Finally, Vermillion & White Wealth Management Group LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at about $62,000. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Down 1.2%

Shares of NASDAQ BMRN traded down $0.72 during trading on Friday, hitting $58.10. 2,032,043 shares of the company traded hands, compared to its average volume of 1,750,220. The company has a 50-day moving average price of $57.51 and a 200-day moving average price of $62.73. BioMarin Pharmaceutical Inc. has a 1 year low of $52.93 and a 1 year high of $94.85. The company has a quick ratio of 3.49, a current ratio of 5.52 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $11.14 billion, a P/E ratio of 21.60, a P/E/G ratio of 0.81 and a beta of 0.17.

Analysts Set New Price Targets

Several research firms have recently weighed in on BMRN. Morgan Stanley assumed coverage on shares of BioMarin Pharmaceutical in a report on Thursday, July 3rd. They set an "overweight" rating and a $97.00 price objective for the company. Citigroup lowered their price objective on shares of BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group decreased their price objective on BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating for the company in a report on Monday, May 5th. Finally, Wall Street Zen raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $93.61.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,786 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the transaction, the chief accounting officer owned 14,173 shares in the company, valued at approximately $840,600.63. The trade was a 11.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.